On December 23, 2024, Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc's subsidiary, sold 2,104 shares of Ligand Pharmaceuticals Inc (LGND, Financial). Following this transaction, the insider now holds 20,647 shares of the company. The details of this transaction can be found in the SEC Filing.
Ligand Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company is known for its business model of licensing its technology to other pharmaceutical companies, which then use it to develop their own products.
Over the past year, Octavio Espinoza has sold a total of 16,812 shares and has not purchased any shares. The insider transaction history for Ligand Pharmaceuticals Inc shows that there have been 1 insider buy and 14 insider sells over the past year.
On the day of the recent sale, shares of Ligand Pharmaceuticals Inc were trading at $116.37, giving the stock a market cap of $2,158.796 million. The company's price-earnings ratio stands at 45.52, which is higher than the industry median of 25.77 and also higher than the company's historical median price-earnings ratio.
With a trading price of $116.37 and a GF Value of $56.32, Ligand Pharmaceuticals Inc has a price-to-GF-Value ratio of 2.07, indicating that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at. It also includes a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
